Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy

Peter H. O'Donnell, Ana Jensen, Edwin M. Posadas, Julia A. Bridge, Anjana V. Yeldandi, Ximing J. Yang, Walter M. Stadler, Hikmat Al-Ahmadie

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.

Original languageEnglish (US)
Pages (from-to)110-114
Number of pages5
JournalNature Reviews Urology
Volume7
Issue number2
DOIs
StatePublished - Feb 2010

Fingerprint

Hemoglobinopathies
Medullary Carcinoma
Kidney
Neoplasms
gemcitabine
Nephrectomy
Sickle Cell Trait
Urinalysis
Kidney Neoplasms
Cytogenetic Analysis
Sickle Cell Anemia
Hematuria
Etoposide
Lymph Node Excision
Doxorubicin
Cisplatin
Disease Progression
Electrophoresis
Hemoglobins
Mothers

ASJC Scopus subject areas

  • Urology

Cite this

O'Donnell, P. H., Jensen, A., Posadas, E. M., Bridge, J. A., Yeldandi, A. V., Yang, X. J., ... Al-Ahmadie, H. (2010). Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nature Reviews Urology, 7(2), 110-114. https://doi.org/10.1038/nrurol.2009.255

Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. / O'Donnell, Peter H.; Jensen, Ana; Posadas, Edwin M.; Bridge, Julia A.; Yeldandi, Anjana V.; Yang, Ximing J.; Stadler, Walter M.; Al-Ahmadie, Hikmat.

In: Nature Reviews Urology, Vol. 7, No. 2, 02.2010, p. 110-114.

Research output: Contribution to journalArticle

O'Donnell, PH, Jensen, A, Posadas, EM, Bridge, JA, Yeldandi, AV, Yang, XJ, Stadler, WM & Al-Ahmadie, H 2010, 'Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy', Nature Reviews Urology, vol. 7, no. 2, pp. 110-114. https://doi.org/10.1038/nrurol.2009.255
O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ et al. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nature Reviews Urology. 2010 Feb;7(2):110-114. https://doi.org/10.1038/nrurol.2009.255
O'Donnell, Peter H. ; Jensen, Ana ; Posadas, Edwin M. ; Bridge, Julia A. ; Yeldandi, Anjana V. ; Yang, Ximing J. ; Stadler, Walter M. ; Al-Ahmadie, Hikmat. / Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. In: Nature Reviews Urology. 2010 ; Vol. 7, No. 2. pp. 110-114.
@article{7fcab3d6f6a4496eaab147d6d66a0816,
title = "Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy",
abstract = "Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.",
author = "O'Donnell, {Peter H.} and Ana Jensen and Posadas, {Edwin M.} and Bridge, {Julia A.} and Yeldandi, {Anjana V.} and Yang, {Ximing J.} and Stadler, {Walter M.} and Hikmat Al-Ahmadie",
year = "2010",
month = "2",
doi = "10.1038/nrurol.2009.255",
language = "English (US)",
volume = "7",
pages = "110--114",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy

AU - O'Donnell, Peter H.

AU - Jensen, Ana

AU - Posadas, Edwin M.

AU - Bridge, Julia A.

AU - Yeldandi, Anjana V.

AU - Yang, Ximing J.

AU - Stadler, Walter M.

AU - Al-Ahmadie, Hikmat

PY - 2010/2

Y1 - 2010/2

N2 - Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.

AB - Background. A 42-year-old white man with no significant prior medical history presented with macroscopic hematuria of 2 months' duration. His family history was notable for a maternal grandfather with kidney cancer. Investigations. Urinalysis, CT, microscopic examination of tumor, immunohistochemical analysis of tumor, hemoglobin electrophoresis, molecular cytogenetic analysis, gene sequencing.Diagnosis. Renal medullary-like carcinoma in an adult without sickle cell trait, sickle cell disease or other hemoglobinopathies.Management. The patient underwent laparoscopic nephrectomy to remove the tumor and received adjuvant sorafenib (400mg per day) as part of the E2805 ASSURE (Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma) trial. Metastatic recurrence of the tumor occurred 9 months after nephrectomy, for which the patient underwent tumor debulking and retroperitoneal lymph node dissection, followed by chemotherapy consisting of gemcitabine (2,000 mg/m 2) and doxorubicin (50 mg/m2), both given on day 1 of a 14-day cycle. After six cycles of drug treatment, the patient had achieved a partial response. The patient was managed by active surveillance for 4 months, when he developed further symptoms and disease progression was detected. Third-line systemic therapy in the form of 21-day cycles of cisplatin (80 mg/m2 on day 1) and etoposide (100 mg/m2 on days 1-3) has recently been initiated.

UR - http://www.scopus.com/inward/record.url?scp=77049115709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77049115709&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2009.255

DO - 10.1038/nrurol.2009.255

M3 - Article

C2 - 20145663

AN - SCOPUS:77049115709

VL - 7

SP - 110

EP - 114

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 2

ER -